Press releaseBusiness Wire
Abcellera Biologics
ABCL · NASDAQ
$11.71−$0.22 (−1.84%)TodayMarket closed ·
Prev close $11.93
Latest news
- Press releaseBusiness Wire
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- Press releasePRNewswire
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
- Press releaseBusiness Wire
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
- NewsVandana Singh
What'sGoing On With AbCellera Biologics Stock On Tuesday?
- Press releaseGlobe Newswire
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Press releaseBusiness Wire
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
- NewsVandana Singh
What's Going on With AbCellera Biologics Stock On Wednesday?
- NewsAvi Kapoor
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Press releaseGlobe Newswire
These Have the Market Hot Zone Catalysts and Setups
- Press releaseBusiness Wire
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- NewsVandana Singh
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
- NewsAvi Kapoor
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
AI Found an Influenza Target That Survives Viral Mutation
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Market-Moving News for August 10th
- Press releaseBusiness Wire
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseBusiness Wire
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
- Press releaseBusiness Wire
AbCellera Reports Q2 2026 Business Results
- Press releaseBusiness Wire
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
- Press releasePRNewswire
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
- Press releasePRNewswire
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Press releaseBusiness Wire
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
- Press releaseBusiness Wire
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
- Press releasePRNewswire
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
- NewsVandana Singh
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
- Press releaseBusiness Wire
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
- Press releaseBusiness Wire
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
- News
12 Health Care Stocks Moving In Monday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.